Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Rectal Neoplasms 1Papillomavirus Infections 1Colonic Neoplasms 1Carcinoma in Situ 1

Interventions

Cyclophosphamide 909Carboplatin 786pembrolizumab 743Paclitaxel 742Cisplatin 708Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 336Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Doxylamine × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT00226941 2017-12-08

A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

Stanford University

Phase 1/2 Terminated
23 enrolled 18 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡